Keqian Biotech: Net profit expected to grow by 9.51% year-on-year in 2025, proposing a dividend of 6.4 RMB per 10 shares.

2026-04-09 07:31:21

People’s Finance News, April 7—Kewen Biotech (688526) disclosed its annual report on April 7. In 2025, the company recorded operating revenue of RMB 950 million, up 0.83%; net profit attributable to shareholders of RMB 419 million, up 9.51%; and basic earnings per share of RMB 0.9. The company plans to distribute a cash dividend of RMB 6.4 (tax inclusive) for every 10 shares. During the reporting period, the veterinary biological products segment was affected by intensified market competition. The company adjusted its sales structure, continued to strengthen internal cost controls, promoted cost reduction and efficiency gains as well as process upgrades, and achieved a cost decrease. For the other product segments, due to business expansion, the group acquired new breeding companies, increasing its scale, which led to a significant increase in investment costs.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.